Evercore downgraded electric car maker Tesla to “underperform” from “in-line” on Monday, citing concerns on the decline in demand across all models.

There are many good reasons to worry about Tesla, including more competition, lower U.S. tax credits and an “aging” product lineup, wrote Evercore analyst Arndt Ellinghorst, who expects these headwinds to weigh on demand and cause a 40% decline in earnings per share by 2020.

Evercore also slashed its 12-month price target for Tesla to $240 from $330, implying 12% downside from Friday’s close. Shares of Tesla are down 1.85% to $268 in premarket trading on Monday.

“The change in recommendation and lower [price target] are driven by a more cautious view on demand across all Models, but in particular the recent severe decline in demand for Model S/X … there is increased uncertainty around near-term demand vs previous bullish forecasts and growth cannot stall for a growth company,” Ellinghorst said in a note to clients Monday.

Shares of Tesla have fallen nearly 18% year to date amid dozens of investigations and lawsuits against the company and CEO Elon Musk. On top of the legal woes, the electric car maker’s production keeps disappointing investors. The company reported weaker-than-expected delivery numbers for the first quarter overall and for its key product Model 3 midsize sedan.

Demand for Tesla electric vehicles is also challenged by the revised tax incentives. The credit for Tesla buyers was halved to $3,750 beginning Jan. 1. Tesla had slashed prices by $2,000 on all models to offset the tax credit reduction.

READ  Levi Strauss IPO seeing high demand, more than 10 times oversubscribed: Sources

“The market used to be concerned about production, we’re now concerned about demand … Without properly refreshing the models, the growth story for Model S/X appears to be over,” Ellinghorst said.

Tesla’s stock would trade more favorably if the company raised $2 billion to $3 billion in equity, the analyst said.



READ SOURCE

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here